Non-exclusive drug discount agreement for Alitretinoin (ATC D11AH04)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Alitretinoin (ATC-Code nach WHO: D11AH04)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No minimum quantity guarantee; actual demand uncertain and beyond supplier control.
Potential early termination of the Open-House if exclusive agreements are signed (estimated 8-12 months after notice).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Aug 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Conclusion of non-exclusive discount agreements for pharmaceutical products with active substance Alitretinoin (ATC D11AH04)
- Open-House model, no negotiations, no exclusivity
Open-House model for non-exclusive discount agreements for Alitretinoin (ATC D11AH04) with AOK PLUS. No guaranteed volumes. Rolling submissions until August 2027.
Risks
No minimum quantity guarantee; actual demand uncertain and beyond supplier control.
Potential early termination of the Open-House if exclusive agreements are signed (estimated 8-12 months after notice).
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG
- Must have registered office in Germany, EU, or EEA
Eligibility
- Self-declaration on exclusion grounds (§§123,124 GWB)
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Alitretinoin (ATC D11AH04)
Conclusion of non-exclusive discount agreements for Alitretinoin under §130a Abs. 8 SGB V. Open-House model, no exclusivity, no minimum quantities.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Alitretinoin (ATC-Code nach WHO: D11AH04)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 06 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 438763-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No minimum quantity guarantee; actual demand uncertain and beyond supplier control.
Potential early termination of the Open-House if exclusive agreements are signed (estimated 8-12 months after notice).
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications